Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Randomized Controlled Trial

doi: 10.1002/ejhf.657. Epub 2016 Oct 28.

Caroline Kistorp 3 4, Pernille Holmager 3, Rasmus Stilling Tougaard 1 2, Roni Nielsen 1 2, Anja Hänselmann 5, Brian Nilsson 6, Jacob Eifer Møller 5, Jakob Hjort 2, Jon Rasmussen 3 4, Trine Welløv Boesgaard 7, Morten Schou 4 8, Lars Videbaek 5, Ida Gustafsson 6, Allan Flyvbjerg 2 9 10, Henrik Wiggers 1 2, Lise Tarnow 7 9 11

Affiliations

PMID: 27790809
DOI: 10.1002/ejhf.657

Free article

Randomized Controlled Trial

Anders Jorsal et al. Eur J Heart Fail. 2017 Jan.

Free article

Abstract

Aims: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.

Methods and results: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04).

Conclusion: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

Keywords: Glucagon-like peptide-1; Heart failure; Heart rate; Left ventricular function; Liraglutide; Type 2 diabetes.

PubMed Disclaimer

Comment in

Liraglutide in heart failure: caution is needed.
Komajda M. Komajda M. Eur J Heart Fail. 2017 Jan;19(1):78-79. doi: 10.1002/ejhf.707. Eur J Heart Fail. 2017. PMID: 28052548 No abstract available.

Cited by

Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life.
Shchendrygina A, Rakisheva A, Giverts I, Rustamova Y, Soloveva A. Shchendrygina A, et al. Card Fail Rev. 2024 Sep 11;10:e10. doi: 10.15420/cfr.2024.05. eCollection 2024. Card Fail Rev. 2024. PMID: 39309521 Free PMC article. Review.
Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction.
Wang TY, Yang Q, Cheng XY, Ding JC, Hu PF. Wang TY, et al. Heart Fail Rev. 2024 Sep 13. doi: 10.1007/s10741-024-10438-2. Online ahead of print. Heart Fail Rev. 2024. PMID: 39269643 Review.
Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis.
Mao T, Chen J, Su T, Xie L, Qu X, Feng R, Pan Y, Wan J, Cui X, Jia W, Gao Q, Lin Q. Mao T, et al. Diabetol Metab Syndr. 2024 Aug 29;16(1):208. doi: 10.1186/s13098-024-01448-z. Diabetol Metab Syndr. 2024. PMID: 39198854 Free PMC article.
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
Holst JJ. Holst JJ. Nat Metab. 2024 Aug 19. doi: 10.1038/s42255-024-01113-9. Online ahead of print. Nat Metab. 2024. PMID: 39160334 Review.
Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study.
Karacabeyli D, Lacaille D, Lu N, McCormick N, Xie H, Choi HK, Aviña-Zubieta JA. Karacabeyli D, et al. PLoS One. 2024 Aug 8;19(8):e0308533. doi: 10.1371/journal.pone.0308533. eCollection 2024. PLoS One. 2024. PMID: 39116084 Free PMC article.

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial - PubMed (original) (raw)